Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-17-029537

Chief Executive Officer acquired 15,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2017-12-21 Option exercise +15,000 $1.81 $27,150 148,560 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2017-12-21 Option exercise · Employee Stock Option (right to buy) −15,000 279,558 D
Loading xslF345X03/doc4.xml…